We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GE HealthCare and UW Medicine Radiology Expand CT, MI Research Tie
Read MoreHide Full Article
Key Takeaways
GEHC launched a research collaboration with UW Medicine Radiology to advance CT and molecular imaging tech.
Partnership aims automated workflows in cardiology, oncology and theranostics to speed clinical translation.
Programs will build evidence for spectral imaging, AI protocols and oncology image-processing solutions.
GE HealthCare Technologies Inc. (GEHC - Free Report) recently entered into a research collaboration with the University of Washington Department of Radiology (UW Medicine Radiology), focused on advancing computed tomography (“CT”) and molecular imaging (“MI”) technologies. The initiative aims to automate workflows across cardiology, oncology and theranostics while supporting faster clinical translation of next-generation imaging technologies.
Per management, molecular imaging and CT are converging more than ever to improve disease detection and characterization throughout the patient journey. The collaboration with UW Medicine Radiology will help to advance imaging technologies that provide more precise, actionable insights and support greater precision in diagnostic imaging innovation.
Likely Trend of GEHC Stock Following the News
Shares of GEHC have lost 0.2% since the announcement on Thursday. In the year-to-date period, shares of the company have fallen 21.7% compared with the industry’s 22.2% decline. However, the S&P 500 has risen 9.6% in the same timeframe.
In the long run, the collaboration strengthens GEHC’s position in advanced diagnostic imaging and precision medicine by deepening its 30-year relationship with UW Medicine Radiology. The partnership provides GEHC with a platform to refine and validate next-generation CT and molecular imaging technologies in real-world clinical settings, supporting broader adoption across global healthcare systems. The initiative also supports GEHC’s strategy of combining AI, automation and imaging hardware to improve workflow efficiency and deliver personalized patient care.
GEHC currently has a market capitalization of $29.22 billion.
Image Source: Zacks Investment Research
More on the Strategic Collaboration
The research collaboration between UW Medicine Radiology and GE HealthCare is focused on advancing CT, MI and theranostics to improve diagnosis, treatment and patient care. The partnership is built around two core programs aimed at accelerating innovation in imaging technologies and clinical workflows.
The CT program seeks to advance CT imaging science and clinical practice through research, collaboration and education. Key efforts include generating clinical evidence to support the adoption of spectral imaging technologies and improving CT workflows through automation and software tools that enhance efficiency for clinicians and patient experiences.
The MI and theranostics initiatives are designed to support personalized cancer care by integrating advanced diagnostic imaging, AI-enabled software and radiopharmaceuticals. The collaboration will focus on developing clinical evidence for innovative imaging protocols, applying deep learning to improve treatment planning and clinical trial matching, and creating advanced oncology imaging and image-processing solutions that enable precise, personalized care.
Industry Prospects Favoring the Market
Going by the data provided by Mordor Intelligence, the U.S. diagnostic imaging market is valued at $10.57 billion in 2026 and is expected to witness a CAGR of 4.5% through 2031.
Factors like the AI-driven workflow and image interpretation, shift of imaging volumes to outpatient and ambulatory settings, rapid penetration of portable and handheld ultrasound/X-ray systems are driving the market’s growth.
Other News
GE HealthCare recently announced a series of advancements in its next-generation SIGNA MR portfolio, including the FDA 510(k)-pending Sonic DL for faster AI-powered 2D imaging, the AI-enabled SIGNA One workflow ecosystem and the next-generation SIGNA Bolt 3T MRI system. The company also introduced the helium-free SIGNA Sprint with Freelium, expanded AIR Recon DL support for ZTE and Silenz imaging and launched SIGNA Studio research collaboration tools. In neuroscience, GE HealthCare announced new installations of its investigational MAGNUS head-only MR scanner at King’s College London and West China Hospital.
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently sporting a Zacks Rank #1, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has a long-term estimated growth rate of 14.6%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Shutterstock
GE HealthCare and UW Medicine Radiology Expand CT, MI Research Tie
Key Takeaways
GE HealthCare Technologies Inc. (GEHC - Free Report) recently entered into a research collaboration with the University of Washington Department of Radiology (UW Medicine Radiology), focused on advancing computed tomography (“CT”) and molecular imaging (“MI”) technologies. The initiative aims to automate workflows across cardiology, oncology and theranostics while supporting faster clinical translation of next-generation imaging technologies.
Per management, molecular imaging and CT are converging more than ever to improve disease detection and characterization throughout the patient journey. The collaboration with UW Medicine Radiology will help to advance imaging technologies that provide more precise, actionable insights and support greater precision in diagnostic imaging innovation.
Likely Trend of GEHC Stock Following the News
Shares of GEHC have lost 0.2% since the announcement on Thursday. In the year-to-date period, shares of the company have fallen 21.7% compared with the industry’s 22.2% decline. However, the S&P 500 has risen 9.6% in the same timeframe.
In the long run, the collaboration strengthens GEHC’s position in advanced diagnostic imaging and precision medicine by deepening its 30-year relationship with UW Medicine Radiology. The partnership provides GEHC with a platform to refine and validate next-generation CT and molecular imaging technologies in real-world clinical settings, supporting broader adoption across global healthcare systems. The initiative also supports GEHC’s strategy of combining AI, automation and imaging hardware to improve workflow efficiency and deliver personalized patient care.
GEHC currently has a market capitalization of $29.22 billion.
Image Source: Zacks Investment Research
More on the Strategic Collaboration
The research collaboration between UW Medicine Radiology and GE HealthCare is focused on advancing CT, MI and theranostics to improve diagnosis, treatment and patient care. The partnership is built around two core programs aimed at accelerating innovation in imaging technologies and clinical workflows.
The CT program seeks to advance CT imaging science and clinical practice through research, collaboration and education. Key efforts include generating clinical evidence to support the adoption of spectral imaging technologies and improving CT workflows through automation and software tools that enhance efficiency for clinicians and patient experiences.
The MI and theranostics initiatives are designed to support personalized cancer care by integrating advanced diagnostic imaging, AI-enabled software and radiopharmaceuticals. The collaboration will focus on developing clinical evidence for innovative imaging protocols, applying deep learning to improve treatment planning and clinical trial matching, and creating advanced oncology imaging and image-processing solutions that enable precise, personalized care.
Industry Prospects Favoring the Market
Going by the data provided by Mordor Intelligence, the U.S. diagnostic imaging market is valued at $10.57 billion in 2026 and is expected to witness a CAGR of 4.5% through 2031.
Factors like the AI-driven workflow and image interpretation, shift of imaging volumes to outpatient and ambulatory settings, rapid penetration of portable and handheld ultrasound/X-ray systems are driving the market’s growth.
Other News
GE HealthCare recently announced a series of advancements in its next-generation SIGNA MR portfolio, including the FDA 510(k)-pending Sonic DL for faster AI-powered 2D imaging, the AI-enabled SIGNA One workflow ecosystem and the next-generation SIGNA Bolt 3T MRI system. The company also introduced the helium-free SIGNA Sprint with Freelium, expanded AIR Recon DL support for ZTE and Silenz imaging and launched SIGNA Studio research collaboration tools. In neuroscience, GE HealthCare announced new installations of its investigational MAGNUS head-only MR scanner at King’s College London and West China Hospital.
GE HealthCare Technologies Inc. Price
GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote
GEHC’s Zacks Rank & Key Picks
Currently, GEHC carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently sporting a Zacks Rank #1, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has a long-term estimated growth rate of 14.6%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.